These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18071311)

  • 1. Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer.
    Baird SK; Aerts JL; Eddaoudi A; Lockley M; Lemoine NR; McNeish IA
    Oncogene; 2008 May; 27(22):3081-90. PubMed ID: 18071311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging.
    Leyton J; Lockley M; Aerts JL; Baird SK; Aboagye EO; Lemoine NR; McNeish IA
    Cancer Res; 2006 Sep; 66(18):9178-85. PubMed ID: 16982761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
    Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
    Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
    Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
    Radhakrishnan S; Miranda E; Ekblad M; Holford A; Pizarro MT; Lemoine NR; Halldén G
    Hum Gene Ther; 2010 Oct; 21(10):1311-25. PubMed ID: 20497039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.
    Flak MB; Connell CM; Chelala C; Archibald K; Salako MA; Pirlo KJ; Lockley M; Wheatley SP; Balkwill FR; McNeish IA
    Mol Cancer; 2010 Jul; 9():175. PubMed ID: 20598155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of an E1A Gene Expression Cassette in an Oncolytic Adenovirus for Efficient Tumor Cell Killing Activity.
    Sakurai F; Nishimae F; Takayama K; Mizuguchi H
    Anticancer Res; 2021 Feb; 41(2):773-782. PubMed ID: 33517282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
    Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
    Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of novel E1-complementary cells for adenoviral production free of replication-competent adenovirus.
    Farson D; Tao L; Ko D; Li Q; Brignetti D; Segawa K; Mittelstaedt D; Harding T; Yu DC; Li Y
    Mol Ther; 2006 Aug; 14(2):305-11. PubMed ID: 16697707
    [No Abstract]   [Full Text] [Related]  

  • 13. Adenoviral E1a expression levels affect virus-selective replication in human cancer cells.
    Zheng X; Rao XM; Snodgrass C; Wang M; Dong Y; McMasters KM; Zhou HS
    Cancer Biol Ther; 2005 Nov; 4(11):1255-62. PubMed ID: 16222119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
    Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
    Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.
    Ingemarsdotter CK; Tookman LA; Browne A; Pirlo K; Cutts R; Chelela C; Khurrum KF; Leung EY; Dowson S; Webber L; Khan I; Ennis D; Syed N; Crook TR; Brenton JD; Lockley M; McNeish IA
    Mol Oncol; 2015 Apr; 9(4):791-805. PubMed ID: 25560085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion analysis of Ad5 E1a transcriptional control region: impact on tumor-selective expression of E1a and E1b.
    Hedjran F; Shantanu K; Tony R
    Cancer Gene Ther; 2011 Oct; 18(10):717-23. PubMed ID: 21818136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication.
    Fechner H; Wang X; Picó AH; Wildner J; Suckau L; Pinkert S; Sipo I; Weger S; Poller W
    J Biotechnol; 2007 Jan; 127(4):560-74. PubMed ID: 17083991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
    Alonso MM; Cascallo M; Gomez-Manzano C; Jiang H; Bekele BN; Perez-Gimenez A; Lang FF; Piao Y; Alemany R; Fueyo J
    Cancer Res; 2007 Sep; 67(17):8255-63. PubMed ID: 17804740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models.
    Cheong SC; Wang Y; Meng JH; Hill R; Sweeney K; Kirn D; Lemoine NR; Halldén G
    Cancer Gene Ther; 2008 Jan; 15(1):40-50. PubMed ID: 18034197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis.
    Tazawa H; Kagawa S; Fujiwara T
    Acta Med Okayama; 2013; 67(6):333-42. PubMed ID: 24356717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.